top of page


What is it?

Photobiomodulation is an innovative treatment that uses specific light wavelengths to improve the function of cells in the retina. While it may not be a miracle cure, it has shown promise in slowing down the rate of visual loss in dry AMD

How is Photobiomodulation administered?

This treatment is administered in a clinical setting using a specialised machine called Valeda, which is made by Lumithera. Patients usually undergo three blocks of treatment each year. Each treatment block aims to slow down the progression of retinal deterioration.

Who can Benefit from Photobiomodulation?

Patients with intermediate dry AMD and those at a high risk of developing geographic atrophy should consider photobiomodulation. While it's exciting and promising, it's important to note that its effectiveness may vary from patient to patient and more research is needed.

What to Expect from Photobiomodulation?
Patients with reasonably good vision may respond well to photobiomodulation, some even experiencing improved visual acuity. However, those with severe visual loss are not likely to notice significant improvements and visual loss will still progress even with treatment but the hope is that it progresses more slowly than it would dwithout treatment.


This groundbreaking treatment is now available for private patients at James Paget University Hospital. For more detailed information, you can also visit Lumithera's website.

Research and Development

It's worth mentioning that ongoing research and development are essential for confirming the initial positive trial results. Photobiomodulation is a new treatment, and its full potential is still being explored.

bottom of page